Can Dexrazoxane and Carvedilol prevent Doxorubicin-induced nephrotoxicity? Cover

.blurhash-client-img { display: none !important; }

Can Dexrazoxane and Carvedilol prevent Doxorubicin-induced nephrotoxicity?

Current Issues in Pharmacy and Medical Sciences

Volume 37 (2024): Issue 4 (December 2024)

By: Jaroslaw Szponar , Agnieszka Gorska , Marta Ostrowska-Lesko , Bartosz Wielgomas and Slawomir Mandziuk

Open Access

|Nov 2024

Authors

Jaroslaw Szponar

Toxicology Clinic, Faculty of Medicine, Medical University of Lublin, Poland

Clinical Department of Toxicology and Cardiology, Stefan Wyszynski Regional Specialist Hospital, Lublin, Poland

Agnieszka Gorska

Toxicology Clinic, Faculty of Medicine, Medical University of Lublin, Poland

Clinical Department of Toxicology and Cardiology, Stefan Wyszynski Regional Specialist Hospital, Lublin, Poland

Marta Ostrowska-Lesko

martaostrowskalesko@umlub.pl

Chair and Department of Toxicology, Medical University of Lublin, Poland

Bartosz Wielgomas

Department of Toxicology, Medical University of Gdansk, Poland

Slawomir Mandziuk

Department of Pneumology, Oncology and Allergology, Medical University of Lublin, Poland

DOI: https://doi.org/10.2478/cipms-2024-0038 | Journal eISSN: 2300-6676 | Journal ISSN: 2084-980X

Journal RSS Feed

Language: English

Page range: 232 - 239

Submitted on: Jun 14, 2024

|

Accepted on: Oct 11, 2024

|

Published on: Nov 28, 2024

Published by: Sciendo

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

post-anthracycline nephrotoxicity,

nephroprotection,

Related subjects:

Clinical medicine,

Clinical medicine, other,

Pharmacology, toxicology,

Pharmacy, other

© 2024 Jaroslaw Szponar, Agnieszka Gorska, Marta Ostrowska-Lesko, Bartosz Wielgomas, Slawomir Mandziuk, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous article Volume 37 (2024): Issue 4 (December 2024)Next article